Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19

Not Applicable

• Conditions: COVID-19
• Interventions: Device: oxyhydrogen; Device: Oxygen

• Registration Number: NCT04336462
• Lead Sponsor: Shanghai Asclepius Meditec Inc.

Brief Summary

This study will evaluate the efficacy and safety of Hydrogen-Oxygen Generator with Nebulizer (model AMS-H-03) developed by Shanghai Asclepius Meditech Co., Ltd. as an adjuvant therapy for the patients with COVID-19 infected pneumonia in improving the clinical symptoms and reducing the incidence of severe pneumonia, as compared with the reference device of EverFlo Oxygen Concentrator (registration certificate No.: NMPA Registration Standard: 20162542389) manufactured by Respironics, Inc. US.

Detailed Description

A multi-center, randomized, parallel-controlled clinical trial design is used in this study.

Eligible subjects will be randomized into the study group and control group in a 1:1 ratio. In addition to the supportive treatments depending on the condition, the subjects in the study group will inhale the mixed gas of hydrogen/oxygen (hydrogen concentration 66%, oxygen concentration 33%) at a flow rate of 6 L/min every day using the Hydrogen/Oxygen Generator with Nebulizer (model AMS-H-03) developed by Shanghai Asclepius Meditech Co., Ltd. during the treatment, with the total use of no less than 6 hours per day, and the other combination treatments will be decided by the investigator depending on the clinical needs; the subjects in the control group will inhale the gas at a flow rate of 2 L/min every day using the reference device of EverFlo Oxygen Concentrator (registration certificate No.: NMPA Registration Standard: 20162542389) developed by Respironics, Inc. US. during the treatment, with the total use of no less than 6 hours per day, and the other combination treatments will be decided by the investigator depending on the clinical needs. During the treatment, the peripheral blood oxygen saturation should be monitored and the oxygen concentration should be increased when necessary (the peripheral oxygen saturation is less than 95% for 30 seconds and other causes have been excluded). Oxygen may be supplied by other devices if the oxygen concentration is sufficient for the subjects in the study group. The oxygen saturation and respiratory rate will be measured at the resting state every day during the treatment, namely after the end of daily treatment and 30 minutes after the inhalation of oxygen and hydrogen/oxygen.

Study Timeline

• Study Start: 2020-02-15
• Primary Completion: 2020-02-21
• Study First Submitted: 2020-03-25
• Status Verified: 2020-04
• Study First Submitted QC: 2020-04-03
• Last Update Submitted: 2020-04-03
• Study First Posted: 2020-04-07
• Last Update Posted: 2020-04-07
• Study Completion: 2020-08-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

All subjects participating in this clinical study must meet all of the following criteria:

1. According to the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 5), under the premise of meeting the diagnostic criteria of moderate COVID-19, the subjects should meet one of the following three conditions:

   ① Respiratory rate (RR): ≥ 20 times/min;

   ② In the state of air absorption and rest, the peripheral oxygen saturation is lower than 95%;

   ③ Arterial partial pressure of oxygen (PaO2)/FiO2: ≤ 400 mmHg (1mmHg=0.133 kPa).

2. ≥18 years old and ≤85 years old subjects with normal autonomous judgment, regardless of gender and region;

3. Subjects voluntarily participate in the study and have signed the informed consent form.

Exclusion Criteria

1. Have other significant diseases other than COVID-19, that is, a disease that, according to the investigator's judgment, can cause the subject to be at risk due to participation in the study, or affect the study results and the ability of the subject to participate in the study.

2. Women who are pregnant or breastfeeding or plan to be pregnant during the study.

3. Subjects with one of the following respiratory diseases:

   1. Asthma: Based on the investigator's judgment, the subjects are currently diagnosed with asthma.
   2. Subjects with a long-term history of COPD and medication or imaging evidence of significant lung structural damage (e.g., giant pulmonary bullae).

   Other respiratory diseases: Subjects with other active pulmonry diseases, such as active tuberculosis, lung cancer, wet bronchiectasis (the high-resolution CT shows bronchiectasis, with yellow sputum every day), sarcoidosis, idiopathic interstitial pulmonary fibrosis (IPF), primary pulmonary arterial hypertension, and uncontrolled sleep apnea (the severity of the disease will affect the implementation of c)the study according to the investigator's judgment), complicated with pneumothorax, pleural effusion, pulmonary embolism, bronchial asthma, tumor, and fever of unknown origin, etc.

   d)Lung volume reduction: Subjects received lung volume reduction, lobectomy, or bronchoscopic lung volume reduction (endobronchial occlusion, airway bypass, endobronchial valve, steam thermal ablation, biological sealant and airway implant) within 6 months.

   e)Subjects in critical or unstable conditions. Critical (meeting any of the following symptoms): 1. Respiratory failure occurs and mechanical ventilation is needed; 2. Shock occurs; 3. With other organ failure, ICU monitoring and treatment is needed.

   f)Risk factors for pneumonia: immunosuppressive diseases (HIV), severe neurological disease affecting upper respiratory tract control, or other risk factors that the investigator believes can cause a significant risk of pneumonia in subjects.

4. Subjects with serious primary diseases of heart, liver, kidney, hematopoietic system and other important organs or systems.

5. Subjects with mental disorder and cognitive impairment.

6. Subjects who do not follow the study steps.

7. Patients with doubts about the effectiveness of informed consent: Subjects with mental illness, mental retardation, poor motivation, drug abuse (including drugs and alcohol) or other disease history restricting the effectiveness of informed consent in this study.

8. Use of non-expectorants and antioxidants, including large doses of vitamin C and vitamen E.

9. Subjects who are not suitable for participation in this study in the judgment of investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
oxyhydrogen	oxyhydrogen	conventional treatment + hydrogen/ oxygen inhaled
oxygen	Oxygen	conventional treatment + oxygen inhaled

Primary Outcome Measures

Name	Time	Method
Recovery time	The day from the patient's admission to the Disease Progression to critical type，up to 2 weeks.	The time from the patient's admission to the Disease Progression to critical type，up to 2 weeks.

Secondary Outcome Measures

Name	Time	Method
Clinical Symptom Remission time	The day from admission to clinical remission,up to 2 weeks.	Clinical Symptom Remission was defined as: The patient's body temperature was normal for more than 72 hours (without taking antipyretics or hormones) and had no conscious dyspnea or decreased dyspnea.
Leicester cough questionaire (LCQ)	The day from admission to clinical remission,up to 2 weeks.	The scale consisted of 19 questions in three domains: physical, psychological and social, each with a score ranging from 1.7. Each item represented an adverse event caused by a cough. The answer was scored on a Likert 7 point scale. The higher the score, the better the health condition. The total score ranged from 7 to 21.
minimum oxygen	The day from admission to clinical remission,up to 2 weeks.	The minimum oxygen absorption flow with 95% oxygen saturation.
Negative conversion rate	the first day to the 14th days.	Negative conversion rate of novel coronavirus nucleic acid in respiratory tract specimens 14 days after enrollment.
Red blood cells(RBC)	The day of admission and clinical remission,up to 2 weeks.	also known as red blood cells, are often abbreviated into RBC in Chinese and English in routine tests. They are the most numerous blood cells in the blood, and also the most important medium for transporting oxygen through the blood in vertebrates. At the same time, they also have immune functions.
white blood cell(WBC)	The day of admission and clinical remission,up to 2 weeks.	White blood cell (WBC) is a colorless, spherical and nucleated blood cell. The total number of normal adults is (4.0-10.0) x 109 / L, which can be changed in a certain range due to different time of day and the functional state of the body.
Hemoglobin(Hb )	The day of admission and clinical remission,up to 2 weeks.	The abbreviation of hemoglobin is HGB or Hb. Hemoglobin is a special protein that transports oxygen in red blood cells. It makes the blood red. It is composed of globin and heme. Its globin part is a tetramer composed of two different pairs of globin chains (α chain and β chain).
Platelets(PLT)	The day of admission and clinical remission,up to 2 weeks.	Platelets are small pieces of cytoplasm released from the cytoplasm of mature megakaryocytes in bone marrow. Although megakaryocytes are the least in the hematopoietic cells of bone marrow, accounting for only 0.05% of the total number of bone marrow nucleated cells, the platelets produced by megakaryocytes are very important for the hemostatic function of the body.
Lymphocyte count	The day of admission and clinical remission,up to 2 weeks.	Lymphocyte count refers to count and calculate the percentage of different types of white blood cells.
Myocardial enzyme	The day of admission and clinical remission,up to 2 weeks.	Myocardial enzyme is a general term for many enzymes existing in the heart, including aspartate aminotransferase (AST), lactate dehydrogenase (LD or LDH), creatine kinase (CK) and isoenzyme, a-hydroxybutyrate dehydrogenase (a-hbd), etc. during acute myocardial infarction, a variety of enzymes in the heart are released due to the necrosis of myocardial cells, so the determination of serum central muscle enzyme is useful for the diagnosis and evaluation of myocardial infarction There is a certain value in the effect of supposition
fever duration	The day from the patient's body temperature was abnormal to normal,up to 2 weeks.	fever duration is the time during the patient's body temperature was abnormal。
Muscle enzyme	The day of admission and clinical remission,up to 2 weeks.	Muscle enzyme generally refers to: phosphocreatine kinase and creatine kinase isoenzyme examination, and some glutamic oxaloacetate transaminase. It is mainly used to check common muscle diseases.
The percentage of lymphocyte	The day of admission and clinical remission,up to 2 weeks.	Lymphocyte has the function of producing and carrying antibody and preventing virus infection. The percentage of lymphocyte was determined by routine blood test, and the normal value was 20.0% - 40.0%. The percentage of lymphocyte increased mainly in infectious diseases and decreased mainly in immune deficiency diseases.
neutrophils	The day of admission and clinical remission,up to 2 weeks.	The membrane of neutrophils can release an unsaturated fatty acid, arachidonic acid. Under the action of enzyme, arachidonic acid can further generate a group of paracrine hormone substances, such as thromboxane and prostaglandin, which play an obvious role in regulating the caliber and permeability of blood vessels, can also cause inflammation and pain, and affect blood coagulation.
liver function	The day of admission and clinical remission,up to 2 weeks.	The purpose of liver function examination is to detect the liver disease, the degree of liver damage, the cause of liver disease, the prognosis and the cause of jaundice. At present, there are many kinds of clinical trials of liver function, no less than dozens. But each kind of liver function test can only detect a certain function of a certain aspect of the liver, so far, there is still no one test that can reflect all the functions of the liver.
Renal function	The day of admission and clinical remission,up to 2 weeks.	Renal function refers to the function of the kidney to excrete the body's metabolic waste, maintain the stability of electrolytes such as sodium, potassium, calcium and acid-base balance. Renal function examination includes blood creatinine, blood urea nitrogen, blood and urine β 2-microglobulin, urinary albumin, urinary immunoglobulin G, urinary secretory immunoglobulin A, etc.
C-reactive protein (CRP)	The day of admission and clinical remission,up to 2 weeks.	C-reactive protein (CRP) is a kind of protein (acute protein) which rises sharply in the plasma when the body is infected or damaged by tissue. It can activate the complement and strengthen the phagocytosis of phagocytes, so as to play a role in regulating. It can clear away the pathogenic microorganism and the damaged, necrotic and apoptotic tissue cells.

Trial Locations

Locations (1)

First Affiliated Hospital of Guangzhou Medical University; 🇨🇳 Guangzhou, Guangdong, China